Denali Capital Acquisition Corp - Ordinary Shares - Class A
NASDAQ:DECA 3:33:22 PM EDT
Mergers / Acquisitions
Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination To Create Nasdaq-Listed Biopharmaceutical Company Focused On Advancing New Technologies To Promote H
Published: 01/26/2023 11:52 GMT
Denali Capital Acquisition Corp - Ordinary Shares - Class A (DECA) - Longevity Biomedical, Inc. and Denali Capital Acquisition Corp.
Announce Business Combination to Create Nasdaq-listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity.
Denali Capital Acquisition Corp - Upon Closing of Transaction Pursuant to Bca, Combined Company Will Operate As Longevity Biomedical, Inc.denali Capital Acquisition Corp-combined Company Will Operate As Longevity Biomedical, Inc., is Expected to List on Nasdaq Under Ticker Symbol "lbio.
".
Denali Capital Acquisition Corp - Transaction Represents a Pro Forma Equity Valuation of Approximately $236.2 Million of Combined Company.
Denali Capital Acquisition Corp - Total Proceeds From Deal Expected to Bring Minimum Pro Forma Cash Balance of $30 Million With Cash Runway Into 2025.
Denali Capital Acquisition - Combined Co May Seek a $30 Million Pre-transaction Pipe That is Expected to Close Concurrently With Closing of Transaction.
Denali Capital Acquisition-estimated Cash Proceeds Available to Combined Company From Transaction Consists of Denali's $85.4 Million of Cash Held in Trust.
Denali Capital Acquisition Corp - Proceeds Will Be Used to Complete Phase 3 Study for Lbi-201, Complete Phase 2 Study for Lbi-001, Complete Phase 2.
Denali Capital Acquisition Corp - Board of Each of Denali and Longevity Unanimously Approved Transaction, Which is Expected to Occur in Q2 2023.
Announce Business Combination to Create Nasdaq-listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity.
Denali Capital Acquisition Corp - Upon Closing of Transaction Pursuant to Bca, Combined Company Will Operate As Longevity Biomedical, Inc.denali Capital Acquisition Corp-combined Company Will Operate As Longevity Biomedical, Inc., is Expected to List on Nasdaq Under Ticker Symbol "lbio.
".
Denali Capital Acquisition Corp - Transaction Represents a Pro Forma Equity Valuation of Approximately $236.2 Million of Combined Company.
Denali Capital Acquisition Corp - Total Proceeds From Deal Expected to Bring Minimum Pro Forma Cash Balance of $30 Million With Cash Runway Into 2025.
Denali Capital Acquisition - Combined Co May Seek a $30 Million Pre-transaction Pipe That is Expected to Close Concurrently With Closing of Transaction.
Denali Capital Acquisition-estimated Cash Proceeds Available to Combined Company From Transaction Consists of Denali's $85.4 Million of Cash Held in Trust.
Denali Capital Acquisition Corp - Proceeds Will Be Used to Complete Phase 3 Study for Lbi-201, Complete Phase 2 Study for Lbi-001, Complete Phase 2.
Denali Capital Acquisition Corp - Board of Each of Denali and Longevity Unanimously Approved Transaction, Which is Expected to Occur in Q2 2023.